Drugs / REGN1400
last change Jan 2015 re-read 3 minutes ago

REGN1400

Developed for
cancer
Investigated by
Regeneron Pharmaceuticals

Trials 1

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01727869 Oct 2012 → Jan 2015 cancer Regeneron Pharmaceuticals Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as REGN1400 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01727869 ↗